The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
Endocrinol Diabetes Metab. 2019 Dec 10;3(4):e00105. doi: 10.1002/edm2.105.eCollection 2020 Oct.
Mazen Noureddin1, Mark D Muthiah23, Arun J Sanyal4
Author information
1Division of Digestive and Liver Diseases Comprehensive Transplant Center Cedars Sinai Medical Center Los Angeles California.
2Department of Medicine Yong Loo Lin School of Medicine National University of Singapore Singapore.
3Division of Gastroenterology and Hepatology National University Hospital National University Health System Singapore.
4Division of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University School of Medicine Richmond Virginia.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in western populations, and is closely associated with features of the metabolic syndrome. The burden of disease is set to rise exponentially, and this is further compounded by the lack of good medications. In addition, these patients tend to have multiple comorbidities that may not be adequately managed. In this article, we review the biological basis of potential therapies in nonalcoholic steatohepatitis (NASH), the current drugs being tested in clinical trials, as well some practical considerations in managing patients in the clinic.